Systemic therapy for hepatocellular carcinoma management perspective

@inproceedings{McNamara2013SystemicTF,
  title={Systemic therapy for hepatocellular carcinoma management perspective},
  author={Mair{\'e}ad Geraldine McNamara and Jennifer J. Knox},
  year={2013}
}
1 ISSN 2045-0923 10.2217/HEP.13.10 © 2014 Future Medicine Ltd Hepatic Oncol. (2014) 1(1), 1–16 Summary Optimal treatment of hepatocellular carcinoma (HCC) is clinically challenging. Systemic treatment for advanced HCC was limited until the approval of sorafenib. This discovery resulted in the advent of many clinical trials. An ongoing Phase III trial is examining the benefit of adjuvant sorafenib. Utilization of doxorubicin-eluting bead embolization may offer safer treatment in eligible HCC… CONTINUE READING